Finance

Lists
Why is SSKN up 100,00%?
Dive Deeper
SSKN:OTCMKTS
STRATA Skin Sciences Inc
0,00020 US$
+100,00%
(+0,00010) 1D
9 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SSKN...
Open
0,00 US$
High
0,00 US$
Low
0,00 US$
Mkt. cap
588,80
Avg. vol.
2,36 ათ.
Volume
182,00
52-wk high
2,65 US$
52-wk low
0,00 US$
EPS
-1,35 US$
Beta
0,06
Shares outstanding
5,89 მლნ.
No. of employees
114
Open
0,00 US$
High
0,00 US$
Low
0,00 US$
Mkt. cap
588,80
Avg. vol.
2,36 ათ.
Volume
182,00
52-wk high
2,65 US$
52-wk low
0,00 US$
EPS
-1,35 US$
Beta
0,06
Shares outstanding
5,89 მლნ.
No. of employees
114
News stories
From web sources and news partners
Seeking Alpha
Seeking Alpha
·
3 საათის წინ
S&P 500 Index Concentration - Room At The Top
Profile
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company's flagship product, XTRAC, is a medical device that allows for a trained dermatologist to treat skin conditions like Vitiligo and Psoriasis with monochromatic UV Light. Following completion of a successful conformity assessment procedure, Strata Skin Sciences has also been granted CE Mark approval for sale of MelaFind in the European Union. In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County. Wikipedia
About STRATA Skin Sciences Inc
CEO-
Employees114
Founded1 იან. 1989
HeadquartersHorsham Township, პენსილვანია, ამერიკის შეერთებული შტატები
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
მარ. 2025
ივნ. 2025
სექ. 2025
დეკ. 2025
Revenue
6,81 მლნ.
7,66 მლნ.
6,93 მლნ.
9,29 მლნ.
Cost of goods sold
3,16 მლნ.
3,36 მლნ.
2,74 მლნ.
3,68 მლნ.
Cost of revenue
3,16 მლნ.
3,36 მლნ.
2,74 მლნ.
3,68 მლნ.
Research and development expenses
96,00 ათ.
86,00 ათ.
172,00 ათ.
67,00 ათ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,57 მლნ.
6,44 მლნ.
5,87 მლნ.
5,51 მლნ.
Operating expense
5,66 მლნ.
6,53 მლნ.
6,04 მლნ.
5,58 მლნ.
Total operating expenses
8,83 მლნ.
9,89 მლნ.
8,79 მლნ.
9,26 მლნ.
Operating income
-2,02 მლნ.
-2,22 მლნ.
-1,86 მლნ.
37,00 ათ.
Other non operating income
-
-
-
-
EBT including unusual items
-2,43 მლნ.
-2,49 მლნ.
-1,62 მლნ.
70,00 ათ.
EBT excluding unusual items
-2,43 მლნ.
-2,49 მლნ.
-2,31 მლნ.
-381,00 ათ.
Income tax expense
-
-
-
12,00 ათ.
Effective tax rate
-
-
-
17,14%
Other operating expenses
-
-
-
-
Net income
-2,43 მლნ.
-2,49 მლნ.
-1,62 მლნ.
58,00 ათ.
Net profit margin
-35,70%
-32,48%
-23,41%
0,62%
Earnings per share
-0,58
-0,60
-0,36
-
Interest and investment income
69,00 ათ.
226,00 ათ.
49,00 ათ.
66,00 ათ.
Interest expense
-486,00 ათ.
-491,00 ათ.
-498,00 ათ.
-484,00 ათ.
Net interest expenses
-417,00 ათ.
-265,00 ათ.
-449,00 ათ.
-418,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-795,00 ათ.
-1,01 მლნ.
-993,00 ათ.
858,00 ათ.
Gain or loss from assets sale
34,00 ათ.
29,00 ათ.
20,00 ათ.
9,00 ათ.
AI content may include mistakes. Learn more
Google აპები